Clinical Trials Clinical Research CRISPR Technology Adeno-Associated Virus Clinical Applications Gene Delivery Systems OTOF Gene Sickle Cell Disease FMR1 Gene SYNGAP1-related Disorders Lentiviral Vectors Neurodegenerative Diseases CRISPR-Cas9 KCNJ2 as a Protective Factor Craniosynostosis Haploinsufficiency AAV Vectors Cardiac Function Usher Syndrome Stem Cell Research HIV Research CCR5 Mutation OTOF Gene Therapy CRISPR Therapeutics Genome Editing Personalized Medicine Spinal Muscular Atrophy Kallikrein Inhibition RNA Technology Huntington's Disease Rare Diseases Adeno-Associated Virus Vector CAR-T Therapy Cyclin A2 Pharmacogenomics SMN1 Gene Viral Vectors SynCav1 Gene Therapy Advances in Gene Therapy Stem Cell Treatment Duchenne Muscular Dystrophy Ophthalmology Adenosine Deaminase Deficiency CPS1 Deficiency Adeno-Associated Viruses Deafness Therapeutic Applications Cardiomyocytes Klotho Protein SCN1A Gene Photoreceptor Function Enzyme Deficiency
Backers see CTX310, CTX320 as single-dose edits that could replace lifelong lipid drugs.
